VenatoRx Pharmaceuticals
PrivateLast Round
Grant
Oct 10, 2023
Total Funding Raised
$329.5M
Company Overview
VenatoRx Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of novel anti-infective agents to treat multi-drug-resistant bacterial and viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VenatoRx Pharmaceuticals Comparables
Compare VenatoRx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allecra Therapeutics | 90% | |
| Antabio | 87% | |
| Fedora Pharmaceuticals Inc. | 85% | |
VenatoRx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 10, 2023 | ||||
| VC Round | Dec 1, 2022 | ||||
| Grant | Oct 3, 2022 | ||||
| Series C | Apr 4, 2022 | ||||
| Grant | Jul 27, 2020 | ||||
Grant | Nov 25, 2019 |
VenatoRx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series C |
| National Institute of Allergy and Infectious Diseases | Grant |
| CARB-X | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Foresite Capital | Series B |
| Versant Ventures | Series B |
| Abingworth | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 10, 2023
$167M grant awarded by BARDA and PHEMCE.
- Oct 3, 2022
$319M grant awarded by BARDA and PEMCE.
VenatoRx Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about VenatoRx Pharmaceuticals's valuation, stock price, and market status.